Sanofi completes acquisition of Vigil Neuroscience to early neurology pipeline
Ella Day | August 6, 2025 | News story | Mergers and Acquisitions |Â Â Alzheimer's disease, Corporate, Neurology, Sanofi, Vigil Neuroscience, neurodegenerative diseasesÂ
Sanofi has announced that it has finalised its acquisition of Vigil Neuroscience, a US-based biotechnology company specialising in neurodegenerative diseases. The deal strengthens Sanofi’s early-stage portfolio in neurology, notably adding VG-3927, an investigational candidate for Alzheimer’s disease currently being prepared for a phase 2 clinical trial.
The acquisition follows a prior investment from Sanofi in June 2024, when the company committed $40m to Vigil, securing rights of first negotiation for VG-3927. With the transaction now complete, Sanofi has acquired all outstanding shares of Vigil for $8 per share in cash, representing a fully diluted equity value of approximately $470m.
In addition to the upfront payment, Vigil shareholders have received a non-transferable contingent value right worth $2 per share, payable upon the first commercial sale of VG-3927.
The transaction excludes VGL101, Vigil’s second clinical-stage programme, which was not included in the acquisition.
VG-3927 targets triggering receptors expressed on myeloid cells 2 (TREM2), a protein implicated in Alzheimer’s and other neurodegenerative disorders. The addition of this candidate and Vigil’s broader preclinical pipeline is expected to expand Sanofi’s research capabilities in neurodegeneration and neurology more broadly.
Sanofi noted that the deal is not expected to impact financial guidance for 2025.
Ella Day
6/8/25
Related Content
Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …
Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition
The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) …
PLL Therapeutics to present ALS research strategy at Bioshares Biotech Summit
French biotech, PLL Therapeutics, will present its approach to early detection and treatment of Amyotrophic …
